HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
Read original at benzingaStocks · News reference
NRx Pharmaceuticals To Host Conference Call And Q&A Session On August 10 To Discuss FDA's Completion Of First-Cycle Review Of Its ANDA For Preservative-Free Ketamine
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&A session on
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 8:03 PM
- Checked
- Aug 7, 2026, 8:03 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
NRX Pharmaceuticals (NASDAQ:NRXP) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Read original at benzinga8-K filing — NRX Pharmaceuticals, Inc. (NRXP)
Filed: 2026-08-17 AccNo: 0001437749-26-028111 Size: 204 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarNRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of $(0.98) per share
Read original at benzinga